Valneva's Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults
Valneva's Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults
On Tuesday, Valneva SE (NASDAQ:VALN) revealed antibody persistence data three years after vaccination with a single dose of its chikungunya vaccine IXCHIQ.
周二，Valneva SE（纳斯达克:VALN）披露了其基孔肯雅IXCHIQ疫苗一剂接种后三年的抗体持久性数据。
The results align with Valneva's expectations for this vaccine, confirming a strong and long-lasting antibody persistence across all age groups investigated.
这些结果与Valneva对该疫苗的预期一致，证实了所有年龄组中抗体持久性强且持久。
The three-year persistence data align with the twelve-month and two-year persistence data the company reported in December 2022 and 2023, respectively.
与公司分别在2022年12月和2023年12月公布的12个月和两年持久性数据一致。
Also Read: European And US Vaccine Stocks Are Under Pressure – Here's Why
也可阅读：欧洲和美国生物-疫苗股票承受压力-原因在这里
Among the 278 healthy adults still enrolled in the trial, 96% maintained neutralizing antibody titers well above the seroresponse threshold three years after the single-dose vaccination. The primary endpoint was, therefore, met.
在仍在试验中的278名健康成年人中，96%的人在单剂疫苗接种后三年保持了远高于血清应答阈值的中和抗体滴度。主要终点因此得以满足。
The persistence of antibodies in older adults (age 65+) in terms of geometric mean titers (GMTs) and seroresponse rates (SRRs) was comparable to younger adults (18-64 years of age).
老年人（65岁以上）的抗体持久性，即几何均数滴度（GMT）和血清应答率（SRR），与年轻成年人（18-64岁）相当。
No safety concerns were reported or identified during the two-year follow-up, and no Adverse Event of Special Interest were ongoing during participant enrollment in the trial.
两年后的随访中未报告或发现安全问题，并且在试验期间，参与者报告没有特殊兴趣的不良事件。
IXCHIQ is the world's first and only licensed chikungunya vaccine.
IXCHIQ是世界上第一款也是唯一一款获许可的基孔肯雅生物-疫苗。
The vaccine is currently approved in the U.S., Europe, and Canada to prevent disease caused by the chikungunya virus in individuals 18 and older.
生物-疫苗目前已在美国、欧洲和加拿大获得批准，用于预防18岁及以上个体感染寨卡病毒引起的疾病。
Valneva recently submitted label extension applications to the FDA, the European Medicines Agency, and Health Canada to potentially extend the use of its chikungunya vaccine IXCHIQ to adolescents aged 12 to 17 years.
Valneva最近向FDA、欧洲药品管理局和加拿大卫生部提交了IXCHIQ寨卡疫苗标签扩展申请，以潜在地将其用于12至17岁青少年。
Juan Carlos Jaramillo, Chief Medical Officer of Valneva, said, "We are extremely pleased about these three-year data which further highlight IXCHIQ's differentiated product profile and ability to induce a robust, long-lasting antibody response in both younger and older adults with a single vaccination."
Valneva首席医疗官Juan Carlos Jaramillo表示：“我们对这三年的数据感到非常满意，进一步凸显了IXCHIQ不同于众的产品特性，以及其能够通过单次接种诱导出强有力且持久的抗体反应，无论是年轻人还是老年人。”
In September, Valneva and Pfizer Inc. (NYSE:PFE) released immunogenicity and safety data from their VLA15-221 Phase 2 study following a second booster vaccination of their Lyme disease vaccine candidate, VLA15, given one year after receiving the first booster dose.
9月，Valneva与辉瑞公司（纽交所：PFE）公布了VLA15-221第2期研究的免疫原性和安全数据，这些数据是在接种他们的莱姆病候选疫苗VLA15的第二次加强剂后一年进行评估的。
One month after receiving the second booster dose, the immune response and safety profile of VLA15 were similar to those reported after receiving the first booster dose, showing compatibility with the anticipated benefit of a booster vaccination before each Lyme season.
在接种第二次加强剂后的一个月，VLA15的免疫反应和安全性与接种第一次加强剂后报告的情况相似，表明与每个莱姆病季之前进行加强接种的期望益处相契合。
Price Action: VALN stock is up 2.58% at $3.97 at last check Tuesday.
股价走势：VALN股票最新报价为3.97美元，周二最新涨幅为2.58%。
- Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
- 摩根士丹利尽管面临2024年的一些挫折，依旧维持对医疗科技的积极展望，升级了直觉外科公司和斯特莱克，降低了对nevro和glaukos的评级。
Image via Shutterstock.
图片由shutterstock提供。
